TIDMGENI
RNS Number : 6154E
GENinCode PLC
30 June 2023
GENinCode Plc
("GENinCode" or the "Company")
Result of AGM
Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics
company focused on the prevention of cardiovascular disease,
announces that at the Annual General Meeting held earlier today,
all resolutions were duly passed.
The voting results of the AGM were as follows:
In Favour Against Withheld
Resolution Votes % Votes % Votes
----------- ------ ---------- ----- -----------
1 46,388,742 99.99 2,846 0.01 0
----------- ------ ---------- ----- -----------
2 34,651,559 96.80 1,145,210 3.20 10,594,819
----------- ------ ---------- ----- -----------
3 46,382,742 99.99 2,846 0.01 6,000
----------- ------ ---------- ----- -----------
4 46,382,742 99.99 2,846 0.01 6,000
----------- ------ ---------- ----- -----------
5 46,382,742 99.99 2,846 0.01 6,000
----------- ------ ---------- ----- -----------
6 46,382,742 99.99 2,846 0.01 6,000
----------- ------ ---------- ----- -----------
7 45,246,378 97.54 1,139,210 2.46 6,000
----------- ------ ---------- ----- -----------
8 46,382,742 99.99 2,846 0.01 6,000
----------- ------ ---------- ----- -----------
9 46,382,742 99.99 2,846 0.01 6,000
----------- ------ ---------- ----- -----------
10 45,252,378 97.54 1,139,210 2.46 0
----------- ------ ---------- ----- -----------
11 46,388,742 99.99 2,846 0.01 0
----------- ------ ---------- ----- -----------
12 46,388,742 99.99 2,846 0.01 0
----------- ------ ---------- ----- -----------
13 45,252,378 97.54 1,139,210 2.46 0
----------- ------ ---------- ----- -----------
14 45,252,378 97.54 1,139,210 2.46 0
----------- ------ ---------- ----- -----------
A copy of the voting results can be found on the website later
today here .
For more information visit www.genincode.com
Enquiries:
GENinCode Plc www.genincode.com or via Walbrook PR
Matthew Walls, CEO
Paul Foulger, CFO
Stifel Nicolaus Europe Limited (Nomad and Joint Broker) Tel: +44 (0)20 7710 7600
Alex Price / Ben Maddison / Richard Short
Cenkos Securities Plc (Joint Broker) Tel: +44 (0)20 7397 8900
Giles Balleny
Dale Bellis / Michael Johnson (Sales)
Walbrook PR Limited Tel: 020 7933 8780 or genincode@walbrookpr.com
Anna Dunphy / Louis Ashe-Jepson / Phillip Marriage
About GENinCode:
GENinCode Plc is a UK based company specialising in genetic risk
assessment of cardiovascular disease. Cardiovascular disease is the
leading cause of death and disability worldwide.
GENinCode operates business units in the UK, Europe through
GENinCode S.L.U, and in the United States through GENinCode U.S.
Inc.
GENinCode predictive technology provides patients and physicians
with globally leading preventative care and treatment strategies.
GENinCode CE marked invitro-diagnostic molecular tests combine
clinical algorithms and bioinformatics to provide advanced patient
risk assessment to predict the onset of cardiovascular disease.
About Cardiovascular Disease (CVD):
CVD is the leading cause of death globally, taking an estimated
17.9 million lives each year. CVD is a group of disorders of the
heart and blood vessels and include coronary heart disease,
cerebrovascular disease, rheumatic heart disease and other
conditions. More than four out of five CVD deaths are due to heart
attacks and strokes, and one third of these deaths occur
prematurely in people under 70 years of age.
CVD causes a quarter of all deaths in the UK and is the largest
cause of premature mortality in deprived areas with the NHS 10 Year
Plan identifying CVD as the single biggest area where the NHS can
save lives over the next 10 years. CVD is largely preventable,
through lifestyle changes and a combination of public health and
NHS action on smoking and tobacco addiction, obesity, tackling
alcohol misuse and food reformulation.
Early detection and treatment of CVD can help patients live
longer, healthier lives. Too many people are still living with
undetected, high-risk conditions such as high blood pressure,
raised cholesterol, and atrial fibrillation (AF). The NHS 10 Year
Plan is working towards people knowing and managing risks around
their 'ABC' (AF, Blood pressure and Cholesterol).
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RAGBUGDLDGXDGXG
(END) Dow Jones Newswires
June 30, 2023 11:03 ET (15:03 GMT)
Genincode (LSE:GENI)
Historical Stock Chart
Von Dez 2024 bis Jan 2025
Genincode (LSE:GENI)
Historical Stock Chart
Von Jan 2024 bis Jan 2025
